Orevandrodeg

Orevandrodeg is a ligand directed degrader (LDD) composed of an E3 ubiquitin ligase-binding moiety that is conjugated, via a linker, to an as of yet undisclosed moiety that targets a prostate specific tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, orevandrodeg specifically and simultaneously targets and binds to the TAA on prostate tumor cells and to E3 ubiquitin ligase, thereby creating a ternary complex. This induces E3 ligase ubiquitination and proteasome-mediated degradation of the TAA. This prevents TAA-mediated signaling and leads to an inhibition of the growth of tumor cells that overexpress the unidentified TAA.